Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Cervical cancer prevention: who should receive vaccination?

Nature Clinical Practice Oncology volume 5, pages 12–13 (2008)Cite this article

boxed-textKoutsky LA et al. (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915–1927

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Harper DM et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247–1255

    Article  CAS  Google Scholar 

  2. Cuzick J et al. (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119: 1095–1101

    Article  CAS  Google Scholar 

  3. Ronco G et al. (2006) Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 98: 765–774

    Article  Google Scholar 

  4. Bulkmans NW et al: High-risk human papillomavirus testing detects cervical intraepithelial neoplasia grade 3 and cancer earlier than cytology in cervical screening permitting extension of the screening interval: five-year follow-up results of the randomised controlled POBASCAM trial. Lancet, in press.

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. at the Department of Pathology, and J Berkhof is a Biostatistician in the Department of Clinical Epidemiology and Biostatistics, CJLM Meijer is Chairman and Director, DAM Heideman is a Senior Scientific Researcher, and PJF Snijders is Head of the Molecular Pathology Unit, all at Vrije Universiteit, Amsterdam, The Netherlands.,

    Chris JLM Meijer, Johannes Berkhof, Daniëlle AM Heideman & Peter JF Snijders

Authors
  1. Chris JLM Meijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Berkhof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniëlle AM Heideman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter JF Snijders
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chris JLM Meijer.

Ethics declarations

Competing interests

CJLM Meijer is a consultant for Digene and has obtained lecture fees from Digene and GlaxoSmithKline. He has received unrestricted grants from GlaxoSmithKline.

The other authors declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meijer, C., Berkhof, J., Heideman, D. et al. Cervical cancer prevention: who should receive vaccination?. Nat Rev Clin Oncol 5, 12–13 (2008). https://doi.org/10.1038/ncponc0976

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0976

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing